ELEV NASDAQ
Elevation Oncology, Inc.
1W: +0.0%
1M: -3.6%
3M: +7.3%
1Y: -86.7%
3Y: -74.1%
$0.36
Last traded 2025-08-01 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$21.6M
52W Range0.221-3.09
Volume4,819,177
Avg Volume1,352,429
Beta1.50
Dividend—
Analyst Ratings
Company Info
CEOJoseph J. Ferra Jr.
Employees34
SectorHealthcare
IndustryBiotechnology
IPO Date2021-06-25
Websiteelevationoncology.com
888 Seventh Avenue
Boston, NY 10106
US
Boston, NY 10106
US
716 371 1125
About Elevation Oncology, Inc.
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Sandler Alan B. | D-Return | 35,000 | $0.31 | 2025-07-23 |
| Sandler Alan B. | D-Return | 35,000 | $3.35 | 2025-07-23 |
| Mootz Darcy | D-Return | 55,000 | $2.74 | 2025-07-23 |
| Mootz Darcy | D-Return | 35,000 | $3.35 | 2025-07-23 |
| Mootz Darcy | D-Return | 35,000 | $0.31 | 2025-07-23 |